AdvisorShares Investments LLC Trims Holdings in Jazz Pharmaceuticals PLC $JAZZ

AdvisorShares Investments LLC lessened its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 50.3% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,140 shares of the specialty pharmaceutical company’s stock after selling 5,200 shares during the quarter. AdvisorShares Investments LLC’s holdings in Jazz Pharmaceuticals were worth $677,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. LSV Asset Management raised its position in shares of Jazz Pharmaceuticals by 3.6% in the 2nd quarter. LSV Asset Management now owns 2,553,742 shares of the specialty pharmaceutical company’s stock worth $271,003,000 after acquiring an additional 87,576 shares in the last quarter. Ameriprise Financial Inc. increased its stake in Jazz Pharmaceuticals by 11.4% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company’s stock valued at $198,159,000 after purchasing an additional 191,637 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Jazz Pharmaceuticals by 3.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,721,294 shares of the specialty pharmaceutical company’s stock worth $182,664,000 after acquiring an additional 59,252 shares during the last quarter. Vestal Point Capital LP purchased a new position in shares of Jazz Pharmaceuticals in the second quarter worth $127,344,000. Finally, Geode Capital Management LLC raised its position in Jazz Pharmaceuticals by 1.5% in the 2nd quarter. Geode Capital Management LLC now owns 1,171,755 shares of the specialty pharmaceutical company’s stock worth $124,366,000 after buying an additional 16,757 shares during the last quarter. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Trading Up 1.4%

Shares of JAZZ opened at $165.50 on Friday. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.65 and a quick ratio of 1.44. The firm has a market capitalization of $10.06 billion, a price-to-earnings ratio of -27.27, a PEG ratio of 0.89 and a beta of 0.26. The company has a 50-day moving average of $167.86 and a 200 day moving average of $145.52. Jazz Pharmaceuticals PLC has a 1-year low of $95.49 and a 1-year high of $182.99.

Wall Street Analysts Forecast Growth

JAZZ has been the subject of a number of research reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research note on Monday, December 29th. Needham & Company LLC increased their price objective on shares of Jazz Pharmaceuticals from $210.00 to $235.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Morgan Stanley reiterated an “overweight” rating and set a $225.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, January 8th. Truist Financial raised their target price on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Finally, UBS Group restated a “neutral” rating and set a $188.00 price target (up previously from $163.00) on shares of Jazz Pharmaceuticals in a report on Monday, November 24th. Fourteen analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $205.67.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, SVP Mary Elizabeth Henderson sold 2,238 shares of the firm’s stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $169.51, for a total transaction of $379,363.38. Following the transaction, the senior vice president owned 19,508 shares of the company’s stock, valued at approximately $3,306,801.08. This trade represents a 10.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Bruce C. Cozadd sold 77,500 shares of the stock in a transaction that occurred on Wednesday, November 26th. The shares were sold at an average price of $177.81, for a total transaction of $13,780,275.00. Following the transaction, the director owned 393,332 shares in the company, valued at approximately $69,938,362.92. This represents a 16.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 123,791 shares of company stock valued at $21,991,850 over the last quarter. 4.30% of the stock is owned by company insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.